vs

Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and SOUTH PLAINS FINANCIAL, INC. (SPFI). Click either name above to swap in a different company.

SOUTH PLAINS FINANCIAL, INC. is the larger business by last-quarter revenue ($54.1M vs $37.2M, roughly 1.5× GYRE THERAPEUTICS, INC.). SOUTH PLAINS FINANCIAL, INC. runs the higher net margin — 26.9% vs -3.7%, a 30.5% gap on every dollar of revenue. Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 5.6%).

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

Ally Financial Inc. is an American bank holding company incorporated in Delaware and headquartered at Ally Detroit Center in Detroit, Michigan. The company provides financial services including car finance, online banking via a direct bank, corporate lending, vehicle insurance, mortgage loans, and other related financing services such as installment sale and lease agreements.

GYRE vs SPFI — Head-to-Head

Bigger by revenue
SPFI
SPFI
1.5× larger
SPFI
$54.1M
$37.2M
GYRE
Higher net margin
SPFI
SPFI
30.5% more per $
SPFI
26.9%
-3.7%
GYRE
Faster 2-yr revenue CAGR
GYRE
GYRE
Annualised
GYRE
17.0%
5.6%
SPFI

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
GYRE
GYRE
SPFI
SPFI
Revenue
$37.2M
$54.1M
Net Profit
$-1.4M
$14.5M
Gross Margin
95.3%
Operating Margin
0.3%
Net Margin
-3.7%
26.9%
Revenue YoY
33.4%
Net Profit YoY
-340.1%
18.3%
EPS (diluted)
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GYRE
GYRE
SPFI
SPFI
Q1 26
$54.1M
Q4 25
$37.2M
$53.9M
Q3 25
$30.6M
$54.2M
Q2 25
$26.8M
$54.7M
Q1 25
$22.1M
$49.2M
Q4 24
$27.9M
$51.9M
Q3 24
$25.5M
$47.9M
Q2 24
$25.2M
$48.6M
Net Profit
GYRE
GYRE
SPFI
SPFI
Q1 26
$14.5M
Q4 25
$-1.4M
Q3 25
$5.9M
$16.3M
Q2 25
$1.6M
$14.6M
Q1 25
$3.7M
$12.3M
Q4 24
$569.0K
Q3 24
$2.9M
$11.2M
Q2 24
$4.5M
$11.1M
Gross Margin
GYRE
GYRE
SPFI
SPFI
Q1 26
Q4 25
95.3%
Q3 25
94.7%
Q2 25
95.7%
Q1 25
95.9%
Q4 24
95.8%
Q3 24
96.2%
Q2 24
96.9%
Operating Margin
GYRE
GYRE
SPFI
SPFI
Q1 26
Q4 25
0.3%
35.4%
Q3 25
22.7%
38.1%
Q2 25
8.1%
34.1%
Q1 25
10.3%
31.9%
Q4 24
2.4%
39.9%
Q3 24
16.6%
29.8%
Q2 24
12.7%
29.3%
Net Margin
GYRE
GYRE
SPFI
SPFI
Q1 26
26.9%
Q4 25
-3.7%
Q3 25
19.4%
30.1%
Q2 25
5.9%
26.7%
Q1 25
16.9%
25.0%
Q4 24
2.0%
Q3 24
11.2%
23.4%
Q2 24
18.0%
22.9%
EPS (diluted)
GYRE
GYRE
SPFI
SPFI
Q1 26
Q4 25
$-0.01
$0.90
Q3 25
$0.03
$0.96
Q2 25
$0.00
$0.86
Q1 25
$0.00
$0.72
Q4 24
$0.00
$0.96
Q3 24
$0.01
$0.66
Q2 24
$0.01
$0.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GYRE
GYRE
SPFI
SPFI
Cash + ST InvestmentsLiquidity on hand
$52.4M
$722.0M
Total DebtLower is stronger
$3.0K
Stockholders' EquityBook value
$106.0M
$504.9M
Total Assets
$166.1M
$4.6B
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GYRE
GYRE
SPFI
SPFI
Q1 26
$722.0M
Q4 25
$52.4M
$552.4M
Q3 25
$60.0M
$635.0M
Q2 25
$54.4M
$470.5M
Q1 25
$29.9M
$536.3M
Q4 24
$26.7M
$359.1M
Q3 24
$25.1M
$471.2M
Q2 24
$25.1M
$298.0M
Total Debt
GYRE
GYRE
SPFI
SPFI
Q1 26
$3.0K
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
GYRE
GYRE
SPFI
SPFI
Q1 26
$504.9M
Q4 25
$106.0M
$493.8M
Q3 25
$101.9M
$477.8M
Q2 25
$92.0M
$454.1M
Q1 25
$68.1M
$443.7M
Q4 24
$63.3M
$438.9M
Q3 24
$63.2M
$443.1M
Q2 24
$60.4M
$418.0M
Total Assets
GYRE
GYRE
SPFI
SPFI
Q1 26
$4.6B
Q4 25
$166.1M
$4.5B
Q3 25
$159.4M
$4.5B
Q2 25
$152.6M
$4.4B
Q1 25
$129.8M
$4.4B
Q4 24
$125.4M
$4.2B
Q3 24
$125.2M
$4.3B
Q2 24
$120.9M
$4.2B
Debt / Equity
GYRE
GYRE
SPFI
SPFI
Q1 26
0.00×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GYRE
GYRE
SPFI
SPFI
Operating Cash FlowLast quarter
$-5.6M
Free Cash FlowOCF − Capex
$-5.8M
FCF MarginFCF / Revenue
-15.5%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GYRE
GYRE
SPFI
SPFI
Q1 26
Q4 25
$-5.6M
$77.5M
Q3 25
$4.7M
$24.2M
Q2 25
$2.1M
$14.7M
Q1 25
$-129.0K
$26.1M
Q4 24
$-2.8M
$59.4M
Q3 24
$1.7M
$17.9M
Q2 24
$-5.5M
$18.2M
Free Cash Flow
GYRE
GYRE
SPFI
SPFI
Q1 26
Q4 25
$-5.8M
$71.8M
Q3 25
$4.0M
$22.5M
Q2 25
$1.8M
$13.0M
Q1 25
$-251.0K
$25.0M
Q4 24
$-2.8M
$56.0M
Q3 24
$1.0M
$17.1M
Q2 24
$-6.9M
$17.1M
FCF Margin
GYRE
GYRE
SPFI
SPFI
Q1 26
Q4 25
-15.5%
133.3%
Q3 25
13.1%
41.5%
Q2 25
6.8%
23.8%
Q1 25
-1.1%
50.8%
Q4 24
-10.1%
108.0%
Q3 24
4.1%
35.7%
Q2 24
-27.5%
35.2%
Capex Intensity
GYRE
GYRE
SPFI
SPFI
Q1 26
Q4 25
0.4%
10.5%
Q3 25
2.2%
3.2%
Q2 25
1.0%
3.2%
Q1 25
0.6%
2.3%
Q4 24
0.2%
6.5%
Q3 24
2.7%
1.6%
Q2 24
5.8%
2.2%
Cash Conversion
GYRE
GYRE
SPFI
SPFI
Q1 26
Q4 25
Q3 25
0.79×
1.48×
Q2 25
1.32×
1.01×
Q1 25
-0.03×
2.12×
Q4 24
-4.85×
Q3 24
0.60×
1.59×
Q2 24
-1.21×
1.63×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GYRE
GYRE

Segment breakdown not available.

SPFI
SPFI

Net Interest Income$42.9M79%
Noninterest Income$11.3M21%

Related Comparisons